Pharma companies are spending billions on a treatment based off old drugs, with little evidence it will extend lives.

As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck & Co.’s cancer immunotherapy Keytruda is one of ...

The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its top-selling immunotherapy Keytruda loses patent protection.

TKI-based regimens remain the primary approach for metastatic renal cell carcinoma after immune checkpoint inhibitor therapy, ...

The experts agreed that perioperative approaches in muscle-invasive bladder cancer continue to evolve. Ongoing data will ...

After a grim diagnosis of Stage IV cancer, a combination of immunotherapy and targeted therapy offered fewer side effects — ...

Merck also lowered revenue guidance for 2025. The stock for pharmaceutical giant Merck (NYSE: MRK) was trading down more than ...